<DOC>
	<DOCNO>NCT02269930</DOCNO>
	<brief_summary>The primary outcome study evaluate cumulative area concentration time curve ( AUC ) 2 week , measure AUC time 0 336 hour post dose ( AUC0-336h ) , serum concentration BIIB017 Rebif . The secondary outcome evaluate maximum observed serum concentration ( Cmax ) BIIB017 Rebif evaluate safety tolerability BIIB017 Rebif 2 week healthy volunteer .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetic Profiles BIIB017 ( Peginterferon Beta-1a ) RebifÂ® ( Interferon Beta-1a ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Must body mass index 19 30 kg/m2 , inclusive , minimum body weight 45.0 kg Screening Day 1 Key History positive test result Screening human immunodeficiency virus , hepatitis C virus antibody current hepatitis B infection ( define positive hepatitis B surface antigen [ HBsAg ] and/or hepatitis B core antibody [ HBcAb ] ) History premalignant malignant disease include solid tumor hematologic malignancy Known allergy interferon component BIIB017 Prior treatment investigational drug within 30 day prior Day 1 , within 5 halflives drug , whichever long NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>